Soleno Therapeutics (SLNO) Competitors $74.86 -0.41 (-0.54%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. SNN, SOLV, PEN, STVN, GKOS, NARI, INSP, BLCO, IRTC, and TMDXShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Smith & Nephew (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Smith & Nephew Solventum Penumbra Stevanato Group Glaukos Inari Medical Inspire Medical Systems Bausch + Lomb iRhythm Technologies TransMedics Group Smith & Nephew (NYSE:SNN) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability. Do analysts rate SNN or SLNO? Smith & Nephew presently has a consensus target price of $27.00, indicating a potential downside of 3.95%. Soleno Therapeutics has a consensus target price of $104.67, indicating a potential upside of 40.25%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Smith & Nephew.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer SNN or SLNO? Smith & Nephew received 128 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 72.62% of users gave Soleno Therapeutics an outperform vote while only 54.16% of users gave Smith & Nephew an outperform vote. CompanyUnderperformOutperformSmith & NephewOutperform Votes44954.16% Underperform Votes38045.84% Soleno TherapeuticsOutperform Votes32172.62% Underperform Votes12127.38% Do insiders & institutionals believe in SNN or SLNO? 25.6% of Smith & Nephew shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by company insiders. Comparatively, 12.3% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is SNN or SLNO more profitable? Smith & Nephew's return on equity of 0.00% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Smith & NephewN/A N/A N/A Soleno Therapeutics N/A -61.99%-55.21% Which has more risk and volatility, SNN or SLNO? Smith & Nephew has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.29, indicating that its share price is 329% less volatile than the S&P 500. Does the media favor SNN or SLNO? In the previous week, Soleno Therapeutics had 3 more articles in the media than Smith & Nephew. MarketBeat recorded 12 mentions for Soleno Therapeutics and 9 mentions for Smith & Nephew. Soleno Therapeutics' average media sentiment score of 1.23 beat Smith & Nephew's score of 0.70 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, SNN or SLNO? Smith & Nephew has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew$5.81B2.12$263M$2.1613.01Soleno TherapeuticsN/AN/A-$38.99M-$4.26-17.52 SummarySoleno Therapeutics beats Smith & Nephew on 9 of the 17 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.72B$3.19B$5.53B$7.73BDividend YieldN/A1.80%5.11%4.22%P/E Ratio-22.4815.3422.4318.38Price / SalesN/A52.75392.01103.07Price / CashN/A44.0938.1834.62Price / Book14.463.506.704.21Net Income-$38.99M$94.03M$3.22B$248.14M7 Day Performance3.08%3.62%2.32%2.54%1 Month Performance3.67%1.87%-0.83%1.02%1 Year Performance67.11%-16.86%17.58%4.92% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.6346 of 5 stars$74.86-0.5%$104.67+39.8%+65.3%$3.74BN/A-22.5530Upcoming EarningsPositive NewsSNNSmith & Nephew1.9656 of 5 stars$25.71-0.8%$27.00+5.0%+9.5%$11.24B$5.81B11.9020,100News CoverageGap UpSOLVSolventum1.504 of 5 stars$64.08-3.3%$79.86+24.6%+0.5%$11.09B$8.25B23.3022,000Analyst ForecastPositive NewsPENPenumbra4.0586 of 5 stars$270.53-2.5%$293.93+8.7%+46.9%$10.47B$1.19B795.683,900Earnings ReportInsider TradeAnalyst RevisionSTVNStevanato Group1.1758 of 5 stars€21.65-1.0%N/A-23.4%$6.56B$1.10B46.064,650Positive NewsGap DownGKOSGlaukos4.7549 of 5 stars$88.17-2.3%$156.17+77.1%-3.8%$4.99B$383.48M-30.72780Gap DownNARIInari MedicalN/A$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.84 of 5 stars$144.74-3.6%$218.90+51.2%-34.5%$4.31B$802.80M83.67760Upcoming EarningsNews CoveragePositive NewsBLCOBausch + Lomb3.8167 of 5 stars$12.05-0.1%$18.82+56.2%-9.3%$4.26B$4.79B-13.2412,500Earnings ReportNews CoverageGap DownIRTCiRhythm Technologies0.9848 of 5 stars$98.63-2.3%$119.73+21.4%-1.8%$3.10B$591.84M-27.101,790Upcoming EarningsNews CoveragePositive NewsTMDXTransMedics Group3.0307 of 5 stars$87.72-0.6%$122.70+39.9%-5.0%$2.97B$441.54M93.32210Analyst ForecastGap Down Related Companies and Tools Related Companies Smith & Nephew Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Inari Medical Alternatives Inspire Medical Systems Alternatives Bausch + Lomb Alternatives iRhythm Technologies Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredYou’re About to Lose Everything – Act Now or Regret It ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
